Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor

IF 6.8 1区医学 Q1 CHEMISTRY, MEDICINAL

Journal of Medicinal Chemistry Pub Date : 2025-01-08 DOI:10.1021/acs.jmedchem.4c02662

Qinda Ye, Artem Shvartsbart, Zhenwu Li, Pei Gan, Rocco L. Policarpo, Chao Qi, Jeremy J. Roach, Wenyu Zhu, Matthew S. McCammant, Bin Hu, Gencheng Li, Haolin Yin, Peter Carlsen, Gia Hoang, Le Zhao, Robert Susick, Fenglei Zhang, Cheng-Tsung Lai, Abdellah Allali Hassani, Leslie B. Epling, Alexandra Gallion, Kerri Kurzeja-Lipinski, Karen Gallagher, Valerie Roman, Matthew R. Farren, Weixi Kong, Marc C. Deller, Guofeng Zhang, Maryanne Covington, Sharon Diamond, Sunkyu Kim, Wenqing Yao, Alexander Sokolsky, Xiaozhao Wang

{"title":"Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor","authors":"Qinda Ye, Artem Shvartsbart, Zhenwu Li, Pei Gan, Rocco L. Policarpo, Chao Qi, Jeremy J. Roach, Wenyu Zhu, Matthew S. McCammant, Bin Hu, Gencheng Li, Haolin Yin, Peter Carlsen, Gia Hoang, Le Zhao, Robert Susick, Fenglei Zhang, Cheng-Tsung Lai, Abdellah Allali Hassani, Leslie B. Epling, Alexandra Gallion, Kerri Kurzeja-Lipinski, Karen Gallagher, Valerie Roman, Matthew R. Farren, Weixi Kong, Marc C. Deller, Guofeng Zhang, Maryanne Covington, Sharon Diamond, Sunkyu Kim, Wenqing Yao, Alexander Sokolsky, Xiaozhao Wang","doi":"10.1021/acs.jmedchem.4c02662","DOIUrl":null,"url":null,"abstract":"The inhibition of mutant KRAS proteins has emerged as a promising approach for treating KRAS-driven cancers, as evidenced by the clinical success of KRAS G12C inhibitors. KRAS G12D, the most common mutant, promises significant expansion of the addressable patient population; however, the reduced nucleophilicity of aspartate compared to cysteine poses significant challenges in balancing sufficient potency with ADME properties to support oral exposure. Herein, we describe the discovery of KRAS G12D inhibitor <b>23</b> (<b>INCB159020</b>), which achieves oral exposure in nonhuman primate (NHP). Starting from a weakly potent hit, structure-based drug design was utilized to drive significant potency. Focus on molecular rigidity and balanced polarity then allowed for successful optimization of properties required for oral exposure.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"99 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-01-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.4c02662","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The inhibition of mutant KRAS proteins has emerged as a promising approach for treating KRAS-driven cancers, as evidenced by the clinical success of KRAS G12C inhibitors. KRAS G12D, the most common mutant, promises significant expansion of the addressable patient population; however, the reduced nucleophilicity of aspartate compared to cysteine poses significant challenges in balancing sufficient potency with ADME properties to support oral exposure. Herein, we describe the discovery of KRAS G12D inhibitor 23 (INCB159020), which achieves oral exposure in nonhuman primate (NHP). Starting from a weakly potent hit, structure-based drug design was utilized to drive significant potency. Focus on molecular rigidity and balanced polarity then allowed for successful optimization of properties required for oral exposure.

Abstract Image

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Medicinal Chemistry 医学-医药化学

CiteScore

4.00

自引率

11.00%

发文量

804

审稿时长

1.9 months

期刊介绍： The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.